| Item | Detail |
|---|
| Closing Price (24 Oct 2026, 12:50 AM CET) | AUD 0.54 |
| Price Change (24 Hours) | +2.94 % |
| Volume Traded (24 Hours) | AUD 64.6 k |
| Shares Outstanding | 345.9 million |
| Market Capitalisation | AUD 119.2 million |
| Simple Moving Average (200 Days) | AUD 0.60 |
| 52‑Week High | AUD 0.80 (11 May 2025) |
| 52‑Week Low | AUD 0.48 (10 Feb 2026) |
| Month‑End Performance (last 30 days) | –0.94 % |
| Ticker | Current Price | Market Capitalisation | Price‑to‑Earnings Ratio | 24‑Hour Change |
|---|
| ECH.AX (Echelon) | AUD 0.34 | AUD 53 m | 17.75 | 0 % |
| HMY.AX (Harmoney) | AUD 0.68 | AUD 77.1 m | 6.79 | +2.22 % |
| BRL.AX (Bathurst) | AUD 0.37 | AUD 64.9 m | – | +1.27 % |
| IKE.AX (Ikegps) | AUD 0.80 | AUD 118.8 m | – | 0 % |
| 8UK.F (New Zealand Rural Land Lt) | EUR 0.44 | EUR 65.8 m | 17.13 | +1.81 % |
Company Overview – Aroa Biosurgery
Aroa Biosurgery Limited operates in the soft‑tissue regeneration sector. The company is headquartered in Auckland, New Zealand, and provides products designed to improve healing rates and quality for complex wounds and soft‑tissue reconstructions. Aroa Biosurgery serves patients, surgeons, and clinicians worldwide. Its shares are listed on the ASX All Markets. The company’s official website is aroabio.com.
